Skip to main content

Ciphergen and M.D. Anderson Cancer Center Sign Ovarian Cancer Biomarker Collaboration

NEW YORK, Feb. 15 (GenomeWeb News) - Ciphergen Diagnostics, a division of Ciphergen Biosystems, has signed a research and license agreement with the University of Texas M.D. Anderson Cancer Center to discover ovarian cancer biomarkers, the company said today.


Under the agreement, M.D. Anderson will provide Ciphergen with clinical samples which Ciphergen will analyze using its ProteinChip mass spectrometry technology and bioinformatics tools. The aim is to validate ovarian cancer biomarkers found earlier, to discover markers to distinguish ovarian cancer from other gynecological disorders, and to predict treatment response.


Ciphergen can exclusively license discoveries from the collaboration, and other cancer projects may be added later to the agreement.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.